• Hoppi

  Participated · Equity · Jun 2026

  Founded in 2024 in Marseille, Hoppi is an online matching platform that connects physicians looking for shifts or posts with hospitals, clinics, EHPADs and other care centers. The company publishes job listings for free and charges recruiters roughly €100 per replacement day completed through its matching service, while not intervening in salary negotiations, contracting or payments. By 2025 Hoppi had relayed 2,000 job listings from 400 establishments and employed seven collaborators, reporting €200,000 in revenue for 2025. Management plans to quadruple listings, expand across France (including public hospitals and interim offers), and recruit additional staff to support growth. Targets for 2026 include €700k–€800k in revenue, 500 establishments using the app and 20,000 physicians on the platform. Longer-term plans include launching a pharmacist-focused subsidiary, enabling placements in under-served cities, pursuing internationalization and raising another funding round around 2028.

• TwoWay

  Participated · Seed · May 2026

  TwoWay combines deterministic proprietary algorithms with AI to parse voice- and chat-driven broker messages and retrieve high-quality pricing data, real-time prices, axes, and market indications. The platform is designed to operate with sub-millisecond predictability and can be deployed on-prem within an institution's infrastructure. TwoWay is already in production with top-tier financial institutions in Paris and London and is being used across FX, Rates, and Fixed Income desks. The company cites that traders currently miss up to 80% of messages, which it estimates costs €1–3M per trader per year in missed opportunities, mispricing, and operational risk. TwoWay plans to deepen its models, expand coverage into rates derivatives, credit, and commodities, and scale the team and deployments across Europe and the UK.

• Bhindi AI

  Participated · Equity · Mar 2026

  Bhindi AI develops an agentic AI platform centered on autonomous "background agents" that plan and execute multistep workflows across disparate applications using natural‑language instructions. The platform includes an agents communication layer enabling specialized agents to cooperate and is described by the founder as a "chat‑to‑action" or "intent‑to‑action" system. Bhindi targets consumer‑facing applications with user activity concentrated in India and the United States. The company traces its origins to Upsurge Labs and was incorporated as Bhindi Labs Pte Ltd in Singapore in January 2024 under CEO Sowmay Jain. Management has indicated product and engineering work will focus on reducing reliance on explicit prompts, improving intent interpretation, and advancing internal data context and memory systems. Bhindi AI has publicly stated prior funding included a $4 million pre‑seed led by Cyber Fund before the later $28 million round.

• Cleavr

  Participated · Seed · Mar 2026

  Cleavr builds an AI platform that automates large portions of the accounts receivable cycle, including reminders, reconciliation, dispute management, and multi-channel communication. The system integrates with existing accounting and ERP systems and uses AI to identify appropriate contacts, process payment commitments, and escalate cases when needed. Unlike fixed-workflow tools, Cleavr adapts communications over time to improve collection outcomes and maintain systematic follow-up. The platform is already adopted by around fifty clients and supports the majority of the collection cycle. Cleavr plans to accelerate deployment in France and expand into broader European markets, with an international rollout targeted for 2026. The company recently raised €1M to fund this expansion.

• Primaa

  Participated · Equity · Oct 2025

  Primaa is a Paris-based medical software company building AI tools that automate and improve cancer diagnostics on digital histology slides. Its flagship Cleo Breast product (CE-IVDR) automatically detects and quantifies key breast-cancer biomarkers, while Cleo Skin, now undergoing CE marking, targets melanoma, squamous cell carcinoma, and basal cell carcinoma. The software reduces processing time, increases diagnostic reliability, and eases workloads for pathologists at institutions such as Institut Curie, AP-HP, and Saint-Joseph Hospital. Early European rollouts are underway at ZAS Laboratory and Liège University Hospital. Primaa is expanding its portfolio with cervical-cancer and prostate-cancer modules being co-developed with clinical partners. Future product plans include predictive AI models that assess disease progression and relapse risk. The company has raised €7 million to date to fund faster European deployment, bolster customer support, and pursue FDA certification for entry into the U.S. market.

No current team members are available.